RT Journal Article
SR Electronic
T1 WORLDWIDE CASE FATALITY RATIO OF COVID-19 OVER TIME
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.04.20206599
DO 10.1101/2020.10.04.20206599
A1 Chaubal, Rohan
A1 Kannan, Sadhana
A1 Khattry, Navin
A1 Gupta, Sudeep
YR 2020
UL http://medrxiv.org/content/early/2020/10/06/2020.10.04.20206599.abstract
AB Background The case fatality ratio (CFR) of coronavirus disease 2019 (COVID-19) has been reported to be variable among different countries and regions but few analyses have tracked this ratio worldwide over time.Methods The primary objective was to assess the time-course evolution of CFR of COVID-19 in all countries with available data and secondary objective was to evaluate associations between country-wise CFR and country-level health, human development, demographic and economic parameters. Day-wise data of COVID-19 cases and deaths for each country was extracted from a public repository and countries with at least 1000 cases on cutoff date were clustered by unsupervised k-means on the basis of deaths per 100000 population (DP100K). Day-wise CFR (cumulative deaths divided by cumulative cases, multiplied by 100) for each country and cluster (country group) was plotted as time-series and country-level parameters were tested for association with CFR using weighted multiple linear regression.Results On September 24, 2020 there were 32140504 cumulative COVID-19 cases and 981792 deaths reported from 184 countries for a worldwide CFR of 3.06 % (95%CI 3.05 -3.07). Unsupervised k-means clustering in 157 countries with at least 1000 reported cases resulted in Clusters (country groups) A, B, C, D and E with centroid DP100K and CFR of 0.100 and 2.51 (95% CI 2.42-2.61), 0.503 and 2.28 (95% CI 2.23-2.33), 1.816 and 1.73 (95% CI 1.71-1.75), 7.395 and 1.76 (95% CI 1.75-1.76), and 36.303 and 3.82 (95% CI 3.82-3.83), respectively. In a log-log analysis DP100K and CFR were significantly positively correlated (R=0.3570, p<0.001) with each other. All country groups and majority of included countries showed a pattern of gradually increasing CFR from the beginning of pandemic, followed by a plateau and then a steady decline in CFR. Among 10 country-level parameters, GDP per capita (β=-0.483, p=0.000), hospital beds per population (β=-0.372, p<0.001), mortality from air pollution (β=-0.487, p=0.003) and population density (β=-0.570, p< 0.000) were significantly negatively associated while maternal mortality ratio (β=0.431, p=0.000) and age (β=0.635, p<0.000) were positively associated with CFR.Conclusions The CFR of COVID-19 has gradually increased over time in majority of countries at various stages of the pandemic, followed by a plateau and a steady decline. Population level COVID-19 mortality burden and CFR are significantly positively associated with each other.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding available for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Declaration: This analysis was performed by academic researchers from a large tertiary cancer centre in India. Institutional ethics committee approval was not sought for this analysis, as per institutional guidelines, because it did not involve collection or handling of individual patient data. All the raw data used in this analysis is available as supplementary filesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the raw data used in this analysis is available as supplementary files